Form 8-K PUMA BIOTECHNOLOGY, INC. For: Feb 28
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Puma Biotechnology (PBYI) PT Raised to $37 at RBC Capital
March 1, 2019 6:51 AM ESTRBC Capital analyst Kennen MacKay raised the price target on Puma Biotechnology (NASDAQ: PBYI) to $37.00 (from $29.00) while maintaining a Sector Perform rating following results.
MacKay called results "unexpectedly impressive" with +16% q/q growth versus a tepid +4% in Q3.
"Inventory confounds the... More
